



Published in final edited form as:

Nat Rev Neurol. 2011 May ; 7(5): 284–294. doi:10.1038/nrneuro.2011.42.

Clinical and pathological features of alcohol-related brain damage

Natalie M. Zahr, Kimberley L. Kaufman, Clive G. Harper

Department of Psychiatry and Behavioral Sciences, 401 Quarry Road, Stanford University, Stanford, CA 94305, USA (N. M. Zahr). Neuropathology Unit, Discipline of Pathology, Blackburn Building, D06, Western Avenue, The University of Sydney, NSW 2006, Australia (K. L. Kaufman, C. G. Harper).

Abstract

One of the sequelae of chronic alcohol abuse is malnutrition. Importantly, a deficiency in thiamine (vitamin B₁) can result in the acute, potentially reversible neurological disorder Wernicke encephalopathy (WE). When WE is recognized, thiamine treatment can elicit a rapid clinical recovery. If WE is left untreated, however, patients can develop Korsakoff syndrome (KS), a severe neurological disorder characterized by anterograde amnesia. Alcohol-related brain damage (ARBD) describes the effects of chronic alcohol consumption on human brain structure and function in the absence of more discrete and well-characterized neurological concomitants of alcoholism such as WE and KS. Through knowledge of both the well-described changes in brain structure and function that are evident in alcohol-related disorders such as WE and KS and the clinical outcomes associated with these changes, researchers have begun to gain a better understanding of ARBD. This Review examines ARBD from the perspective of WE and KS, exploring the clinical presentations, postmortem brain pathology, *in vivo* MRI findings and potential molecular mechanisms associated with these conditions. An awareness of the consequences of chronic alcohol consumption on human behavior and brain structure can enable clinicians to improve detection and treatment of ARBD.

Introduction

Alcoholism is an addictive disorder with multi faceted biological underpinnings (Box 1). Frequent concomitants of alcoholism are liver disease (steatosis, hepatitis and cirrhosis),¹ cardiovascular disease² and mal nutrition.³ The neurological consequences associated with this addictive disorder include hepatic encephalopathy, Wernicke encephalopathy (WE), Korsakoff syndrome (KS), Marchiafava–Bignami disease (MBD) and central pontine myelinolysis (CPM). Each of these relatively well-characterized alcohol-related CNS disorders is associated with a unique clinical presentation and a discrete neuropathological

Correspondence to: C. G. Harper, clive.harper@sydney.edu.au.

Author contributions

The authors all contributed to researching data for the article, discussion of content and writing. N. M. Zahr reviewed the manuscript before submission.

Competing interests

The authors declare no competing interests.

and neuroradiological signature (Figure 1).⁴ The structural changes to the brain and functional consequences that occur with chronic alcohol consumption in the absence of diagnosable neurological concomitants of alcoholism (that is, in cases of uncomplicated alcoholism) are grouped under the term ‘alcohol-related brain damage’ (ARBD).

Whether ARBD represents one end of a continuum of neurological deficits, with disorders such as KS and MBD at the other end,⁵ or one outcome in a range of discontinuous, graded deficits occurring with chronic alcohol exposure and, for example, aging⁶ remains unclear. In addition, whether people with certain genotypes (for example, individuals who are genetically susceptible to malnutrition or liver compromise) are at a greater risk of particular neurological conditions and, consequently, are more likely to express specific alcoholism-related neuropsychological compromise than are individuals with a different genetic make-up remains to be determined. Our objective here is to describe a potential continuum between ARBD, WE and KS with respect to changes in human behavior and brain structure. Note that while this Review is extensive, it is not intended to be exhaustive.

The Wernicke–Korsakoff syndrome

WE is an acute, potentially reversible neurological disorder caused by a deficiency in or severe depletion of thiamine (vitamin B₁) that can result from chronic alcoholism, poor nutrition, long-term parenteral feeding, hyperemesis gravidarum or bariatric surgery.^{7,8} Incidence rates of WE in the general population—on the basis of autopsy findings in Western countries—range from 0.1–2.8%, but can be as high as 12.5% in patients with alcoholism.^{9,10} Such individuals are at a high risk of thiamine deficiency because of the poor diet associated with their lifestyle, and the fact that chronic alcoholism compromises thiamine absorption from the gastrointestinal tract, impairs thiamine storage, and may reduce the phosphorylation of thiamine to its biologically active form, thiamine pyrophosphate (TPP; Figure 2).^{11–15}

Guidelines for the diagnosis, treatment and prevention of WE have been released by the European Federation of Neurological Societies (EFNS), and are based on three decades of research into this condition (Box 2).¹⁶ If WE is recognized, treatment with thiamine can result in rapid clinical improvement.¹⁰ Indeed, the prevalence of WE has been reduced in a number of countries (including the US, the UK and Australia) that have instituted nationwide thiamine supplementation in staple foods such as bread.¹⁷

When WE is left undiagnosed and untreated, ≈80% of patients with this condition develop KS, a severe, typically permanent neurological disorder characterized by anterograde amnesia.¹⁸ The term Wernicke–Korsakoff syndrome (WKS) is used to denote the range of brain and behavioral impairments associated with thiamine deficiency.^{19,20}

Clinical and psychological features

Clinicians are often taught to diagnose WE on the basis of the presence of the classic clinical triad of ocular motor abnormalities, cerebellar dysfunction, and altered mental state. Ocular motor abnormalities occur in ≈30% of patients with WE and may include nystagmus or ophthalmoplegia, while cerebellar dysfunction can be found in ≈25% of patients with this

disorder and may manifest as loss of equilibrium, incoordination of gait, trunk ataxia, dysdiadochokinesia and, occasionally, limb ataxia or dysarthria. Approximately 80% of patients with WE exhibit an altered mental state, which may comprise mental sluggishness, apathy, impaired awareness of an immediate situation, an inability to concentrate, confusion or agitation, hallucinations, behavioral disturbances mimicking an acute psychotic disorder, or coma.^{3,10,21} A retrospective analysis of the clinical signs and symptoms of patients diagnosed at autopsy as having WE revealed that only 20% of patients with this disorder presented with the full triad of clinical features and \approx 30% of such individuals exhibited only cognitive impairment.²¹ Thus, through the requirement of the full triad for a positive diagnosis, WE is missed by routine clinical examination in 75–80% of cases, even in teaching hospitals. By contrast, the presence of just two of four signs (dietary deficiency, ocular motor abnormality, cerebellar dysfunction, and either altered mental state or mild memory impairment), which was first suggested by Caine and colleagues²² and is now recommended by the EFNS,¹⁶ can significantly improve the diagnostic accuracy for WE.

The most salient characteristic of KS is global amnesia.¹⁸ Neuropsychological assessments of multiple functional domains targeting executive functions, declarative and procedural memory, visuospatial abilities and postural stability have revealed that individuals with KS have severe deficits in memory for new material and in gait and balance, despite sparing of general intelligence, short-term memory and visuo-perceptual implicit learning.^{23–26} Patients with KS may also exhibit prefrontal neurobehavioral dysfunction, expressed as deficits on tests of problem solving, working memory, cognitive flexibility, perseverative responding, and self-regulation.^{27–29}

Over 80% of individuals with uncomplicated alcoholism (that is, ARBD) are estimated to show cognitive deficits in executive functions,^{30,31} although such deficits are mild in comparison with those observed in patients with KS.³² Individuals with uncomplicated alcoholism also demonstrate deficits in explicit memory, visuospatial processes and motor control (for example, speed, gait and balance; Figure 3).^{33,34}

The neuropsychological expression of ARBD is marked by heterogeneity in the extent (severity) and type (component) of deficit, and not all individuals with uncomplicated alcoholism exhibit impairments in all the functions described above.³³ Similarly, not all patients with KS have permanent amnesia.³⁵ This heterogeneity suggests that the functions affected by chronic alcohol consumption are dissociable and supported by different neural systems.³⁶ One study examined the component processes of episodic memory (memory of autobiographical events) and working memory (the ability to hold information ‘online’ while doing complex tasks) in individuals with uncomplicated alcoholism and patients with alcoholism and KS. The former could generally be differentiated from the latter via performance on tests of episodic memory (that is, the two groups showed graded impairment in episodic memory), despite significant overlap in performance on working-memory tasks between the two groups (that is, continuous impairment was seen between the two groups).³⁷ On the basis of these findings, the study’s researchers suggested that impairment of episodic memory was the result of the untoward effects of alcohol on the Papez (limbic) circuit and was exacerbated by thiamine deficiency, while the observed impairment in

working memory, which was not specific to KS, may have reflected the effects of chronic alcohol consumption on frontocerebellar circuitry.³⁸

In an attempt to explain the cognitive heterogeneity commonly seen in patients with alcoholism, a recent prospective study applied the operational criteria of Caine and colleagues to a group of individuals with uncomplicated alcoholism, so as to determine whether the presence of any of the four signs, determined by history or current examination, could be used to predict performance on a battery of neuropsychological tests. Among the 56 patients with uncomplicated alcoholism who were assessed, 16% displayed two or more signs, 57% showed only one sign, and 27% met no criteria. In this sample of sober, community-dwelling individuals, self-reported dietary deficiency ($n = 29$) and cerebellar dysfunction (that is, ataxia; $n = 20$) were frequently described, while oculomotor abnormalities ($n = 2$) and mental impairment ($n = 0$) were rarely observed.³⁹ This study revealed a graded effect in cognitive and motor performance among patient subgroups: individuals with alcoholism who did not meet any criteria performed at levels equivalent to healthy controls, whereas patients with one sign showed mild-to-moderate neuro psychological deficits, and patients with two or more signs showed the most severe deficits on each neuro psychological domain evaluated. This graded effect suggests that the heterogeneity in the severity of cognitive and motor deficits seen in patients with uncomplicated alcoholism can be accounted for, in part, by the number of WE signs present.

Postmortem pathological features

The neuropathological changes observed in WKS, as described by Victor and Adams in the early 1970s, include lesions in periventricular regions around the third and fourth ventricles, and atrophy of the mamillary bodies.⁴⁰ By contrast, traditional clinical pathological methods have only been able to demonstrate mild cerebral atrophy and lower mean brain weight in cases of uncomplicated alcoholism.^{41–43} Thus, quantitative studies are required to characterize the relatively subtle structural abnormalities in the brain that are caused by the direct effects of alcohol (Box 3).

In one quantitative study, brain volume with respect to intracranial cavity volume was determined and the mean pericerebral space was shown to rise from 8.3% of the total intracranial cavity volume in healthy controls to 11.3% in patients with ARBD and 14.7% in patients with WKS.⁴⁴ Stereometric studies have suggested that this reduction in brain volume is largely accounted for by the shrinkage of white matter.^{45–47} Cerebellar white matter volume (especially in the vermis) is reduced⁴⁸ and the corpus callosum area is significantly thinned in individuals with alcoholism,^{49,50} especially those with nutritional deficiencies,⁵¹ compared with healthy controls. This finding may represent a dose effect of alcohol rather than an effect of thiamine deficiency, as white matter volume was negatively correlated with maximum daily alcohol consumption.⁴⁷ The nature of the white matter loss remains unknown; however, this phenomenon probably involves changes in both myelination and axonal integrity.⁵²

In addition to atrophy of the mamillary bodies, WKS reveals neuronal loss in the anterior principal and medio-dorsal nuclei of the thalamus⁵³ and in the basal forebrain.⁵⁴ In patients

with alcoholism and signs of WE, a reduction in Purkinje cell density and molecular layer atrophy are noted in the cerebellum, suggesting that this brain region is selectively vulnerable to thiamine deficiency.⁵⁵ In patients with uncomplicated alcoholism, microscopic studies have revealed an $\approx 25\%$ loss of pyramidal neurons in the superior frontal and frontal association (dorsolateral portion) cortices.^{56,57} Little evidence exists for neuronal loss in the primary motor cortex in ARBD. However, a silver impregnation technique has shown that pyramidal neurons in both the superior frontal and motor cortices have dendritic arbor shrinkage,⁵⁸ indicating compromise in interneuronal communication. Dendritic shrinkage has been shown to be reversible in a rodent model of alcoholism following a prolonged period of abstinence.⁵⁹ Subcortical regions of brains from patients with uncomplicated alcoholism exhibit neuronal loss in the supraoptic and para ventricular nuclei of the hypothalamus that shows a positive correlation with maximum daily alcohol consumption.⁶⁰ With respect to the cerebellum, pathological studies do not consistently show a decrease in the number of neurons in cases of ARBD compared with normal controls, suggesting that chronic alcohol consumption *per se* does not necessarily cause neuronal death in this region of the brain. No changes have been documented in the number of neurons in the basal ganglia,⁶¹ hippocampus^{57,62} or serotonergic raphe nuclei⁶³ in ARBD.

***In vivo* MRI features**

MRI has shown that patients with KS have an increase in cerebrospinal fluid volume and widespread gray matter volume deficits.^{5,64} Moreover, group analysis has revealed substantial volume changes in the mamillary bodies of individuals with KS,^{65,66} although mamillary body shrinkage is not a necessary concomitant of this condition.^{3,67} MRI has also demonstrated volume losses in the orbito-frontal cortices and other hypothalamic nuclei in KS.⁵ The volume losses that best differentiate KS from uncomplicated alcoholism, however, involve the thalamus.⁶⁸ In acute WE, MRI can be used to detect symmetrical, bi lateral hyperintense foci (clearly visible on T2-weighted and fluid-attenuated inversion recovery images) in peri-aqueductal gray matter, the mamillary bodies, and the tissue surrounding the third ventricle.^{5,69}

In patients with uncomplicated alcoholism, MRI studies have generally confirmed postmortem studies by demonstrating that such patients have regional cortical volume deficits,^{64,70} especially in the frontal lobes.^{71,72} Among individuals with alcoholism, cerebral shrinkage is more pronounced in older patients than in younger patients, suggesting that the aging brain is especially susceptible to ARBD.^{70,73} Structural MRI has also demonstrated that individuals with alcoholism have significant volume deficits in the corpus callosum^{74,75} and cerebellar white matter.^{48,76} In contrast to postmortem findings, MRI has provided *in vivo* evidence for volume deficits in the anterior hippocampus of patients with chronic alcoholism.^{77,78} These deficits are potentially accounted for by a loss of non-neuronal cells; that is, glia. Altogether, use of MRI to characterize WKS structural brain changes in the context of the neuropathology of uncomplicated alcoholism has revealed a graded pattern of volume deficits (from mild deficits in ARBD to moderate or severe deficits in WKS) in the mamillary bodies, hippocampus, thalamus, cerebellum and pons (Figure 4).⁵ As brain regions outside those traditionally associated with thiamine depletion (for example, the frontal cortices, hippocampus and pons) are affected in both uncomplicated alcoholism

and KS, alcoholism alone or in combination with nutritional deficiencies may have roles in the mechanisms underlying these brain abnormalities. Indeed, multiple subclinical episodes of thiamine deficiency or other nutritional deficiencies may contribute to the graded nature of brain regional volume deficits and to the heterogeneity in presenting signs and neuro-radiological profiles in patients with alcoholism.⁷⁹

In contrast to postmortem studies, *in vivo* magnetic resonance (MR) modalities constitute safe, noninvasive methods for longitudinal examination of the condition of the brain in patients with alcoholism during the natural course of chronic alcohol consumption, detoxification, abstinence or relapse. Such MR studies have demonstrated that some structural brain changes are reversible with prolonged abstinence from alcohol.^{72,80–82} Indeed, ARBD may have two components, one of which is transient and the other being permanent.⁸³ If brain volume loss is due to neuronal loss, brain volume recovery will be incomplete with abstinence. For example, some MR spectroscopy studies have shown that in spite of prolonged abstinence, individuals who have chronically consumed alcohol demonstrate persistent *N*-acetylaspartate (a putative marker of neuronal integrity) decreases in the frontal lobes,^{84–86} the thalamus⁸⁶ and the cerebellum.^{86,87} Other studies, however, have found improvements in the levels of *N*-acetylaspartate and choline—another metabolite that may indicate remyelination—with abstinence.^{88–90} Structural repair of myelin could explain the increase in white matter volume that has been shown to occur after periods of abstinence from alcohol.^{91–93}

Another advantage of *in vivo* MR tools is the facility to conduct behavioral experiments concurrently with imaging, so as to determine brain structure–function relationships. Combined neuropsychological and neuroimaging studies suggest that the amnesia observed in KS may be caused by interruption of a complex diencephalic–hippocampal circuitry that includes thalamic nuclei and mamillary bodies, rather than through an insult to a single node in the circuit such as the hippocampus.⁹⁴ This hypothesis has received support from a study using a novel ‘resting state’ functional MRI analysis, which demonstrated that improvement in memory function in patients recovering from WE parallels the level of mammillothalamic ‘functional connectivity’.⁹⁵ Diffusion tensor imaging (DTI), which is particularly useful in the characterization of the integrity of white matter microstructure, supports a positive correlation between disruption of the microstructural integrity of the corpus callosum and deficits in visuospatial performance, gait and balance.^{81,96–98} In addition to confirming the contribution of cerebellar white matter volume loss (especially in the vermis) to ataxia in patients with chronic alcoholism, combined brain imaging and neuropsychological methods have demonstrated the importance of frontocerebellar connections⁹⁹ to cognitive and sensory functioning,^{100–102} including perceptual motor tasks, executive functions, and learning and memory.^{99,103,104} Improvements with abstinence in brain structure and biochemical status have been demonstrated¹⁰⁵ that correspond with improvement or reversal of functional deficits in working memory, postural stability and visuospatial ability.^{106,107}

Molecular features

A number of incompletely understood, mutually inclusive mechanisms have been proposed to explain how ethanol causes brain damage (Box 4). These mechanisms include

neurotoxicity of the ethanol molecule itself, and the consequences of nutritional deficiencies or liver dysfunction, each of which can lead to the intriguing possibility of alcohol-induced neuroinflammation.

Neuroinflammation is considered to be involved in the pathogenesis and progression of many neurodegenerative disorders,^{108,109} and a mechanistic role for this process in ARBD has recently been proposed.¹¹⁰ The brain cells that might mediate neuroinflammation are microglia, which can exist in multiple states, with the activation of these cells resulting in either anti-inflammatory or pro-inflammatory responses.¹¹¹ A recent study investigated several markers of brain inflammation in 'brain bank' tissue from patients with alcoholism and individuals who had moderate levels of alcohol consumption. Various patterns of positive signs of neuroinflammation were identified in the ventral tegmental area, substantia nigra, hippocampus and amygdala in the individuals with alcoholism,¹¹⁰ providing some support for a mechanistic role for inflammation in alcohol-related alterations to the brain reward system.

As described above, individuals with alcoholism have a high risk of thiamine deficiency because of poor nutrition, impaired absorption of thiamine from the gastrointestinal tract, and reduced liver stores.¹¹² Moreover, alcohol interferes with the conversion of thiamine to its metabolically active form, namely TPP.¹¹³ A reduction in TPP levels disrupts the following processes: carbohydrate metabolism, thereby interrupting energy production through the Krebs cycle and pentose phosphate pathway; lipid metabolism, thereby interrupting the production and maintenance of myelin; and amino acid metabolism, thereby interrupting the production of glucose-derived neurotransmitters.¹⁰ These metabolic deficits can contribute to neuronal and white matter damage.

Bouts of thiamine deficiency may occur in upwards of 80% of patients with alcoholism;^{114,115} however, only \approx 13% of such individuals develop WKS,¹¹⁶ raising the possibility that a genetic predisposition to WKS may exist in some individuals.¹⁵ Some studies have shown that transketolase binds TPP less effectively in patients with WKS than in healthy controls.^{117,118} No consistent correlation, however, has been found between transketolase variants and thiamine deficiency.¹¹⁹ Other genetic loci or variants associated with WKS susceptibility include the X-linked transketolase-like 1 gene,¹²⁰ the high-affinity thiamine transporter protein gene *SLC19A2*,¹²¹ the γ -aminobutyric acid A receptor subunit gene cluster on chromosome 5q33,¹²² and the aldehyde dehydrogenase-2 *ADH2* allele.¹²³ One possibility is that several genetic variants and environmental factors must be present to generate a WKS phenotype, which only becomes clinically relevant when an individual's diet is deficient in thiamine.¹⁰

In recent years, high-throughput genomic and proteomic approaches have been used extensively to provide clues about the molecular mechanisms underlying ARBD. Oligonucleotide and complementary DNA microarray studies of samples of human frontal cortex from individuals with alcoholism have identified alcohol-responsive genes relating to several broad categories, namely myelination, synaptic structure, mitochondria, signal transduction, intracellular metabolism, protein trafficking, apoptosis and transcriptional regulation.^{124–127} Moreover, samples of human temporal cortex from patients with

alcoholism have exhibited changes in the expression of genes encoding proteins related to mitochondria, the ubiquitin system or signal transduction.¹²⁸ Alcohol-responsive genes expressed in the nucleus accumbens and the ventral tegmental area are primarily associated with changes in neurotransmission and signal transduction, suggesting neuroplastic changes that may contribute to changes in reward response. The results of such genomic approaches suggest that multiple pathways may be involved in causing altered neuronal function and structural changes in ARBD, although changes in myelin-related genes seem particularly important. Indeed, altered expression levels of proteolipid protein and myelin basic protein, both of which are involved in stabilization and compaction of the myelin sheath,^{129,130} could explain the structural and functional changes in white matter in patients with alcoholism.¹³¹

Protein expression studies have been conducted in various brain regions including the occipital cortex,¹²⁷ hippo campus¹³² and cerebellum.¹³³ Again, while such studies suggest that several pathways may be associated with ARBD, relevant protein expression studies in patients with uncomplicated alcoholism show dysregulation of key energy-regulating and metabolic proteins, notably those involved in thiamine-dependent cascades in prefrontal gray and white matter,^{134,135} cerebellar vermis¹³³ and corpus callosum.^{136,137} These findings lend weight to the continuum hypothesis of ARBD, WE and KS.

Conclusions

We have described a potential continuum between ARBD, WE and KS with respect to changes in human behavior and brain structure. The clinical diagnosis of ARBD and WE remains difficult; however, an awareness of current research findings and a high index of suspicion can aid in the detection of these conditions. An intimate relationship seems to exist between alcohol use and thiamine deficiency, and we hypothesize that both ARBD and WE may develop as a result of repeated episodes of subclinical thiamine deficiency.¹³⁸ Neuroradiological examination (with MRI) is a valuable tool in the diagnosis of acute WE and enables *in vivo* tracking of the progression of brain pathology from ARBD to KS. An awareness of the facts presented herein by clinicians and other health workers could help minimize the overall burden of ARBD. Moreover, public education programs should be promoted so that individuals using alcohol become aware of the associated risks and gain an understanding that components of the structural and functional changes linked to alcohol use are potentially reversible with abstinence.

Acknowledgments

The authors would like to thank E. V. Sullivan for her invaluable support and advice in preparing this Review. The authors would also like to thank A. Pfefferbaum for contributing the illustrations.

References

1. Lieber CS Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. *Alcohol* 34, 9–19 (2004). [PubMed: 15670660]
2. Hillbom M, Juvela S & Karttunen V Mechanisms of alcohol-related strokes. *Novartis Found. Symp* 216, 193–204 (1998). [PubMed: 9949794]
3. Victor M, Adams RD & Collins GH The Wernicke–Korsakoff Syndrome and Related Neurologic Disorders due to Alcoholism and Malnutrition, 2nd edn (Davis FA, Philadelphia, 1989).

4. Zuccoli G et al. Neuroimaging findings in alcohol-related encephalopathies. *AJR Am. J. Roentgenol* 195, 1378–1384 (2010). [PubMed: 21098198]
5. Sullivan EV & Pfefferbaum A Neuroimaging of the Wernicke–Korsakoff syndrome. *Alcohol Alcohol.* 44, 155–165 (2009). [PubMed: 19066199]
6. Oscar-Berman M & Marinkovic K Alcoholism and the brain: an overview. *Alcohol Res. Health* 27, 125–133 (2003). [PubMed: 15303622]
7. Harper C Thiamine (vitamin B1) deficiency and associated brain damage is still common throughout the world and prevention is simple and safe! *Eur. J. Neurol* 13, 1078–1082 (2006). [PubMed: 16987159]
8. Burns EM et al. Introduction of laparoscopic bariatric surgery in England: observational population cohort study. *BMJ* 341, c4296 (2010). [PubMed: 20798224]
9. Thomson AD, Cook CC, Touquet R & Henry JA The Royal College of Physicians report on alcohol: guidelines for managing Wernicke’s encephalopathy in the accident and emergency department. *Alcohol Alcohol.* 37, 513–521 (2002). [PubMed: 12414541]
10. Sechi G & Serra A Wernicke’s encephalopathy: new clinical settings and recent advances in diagnosis and management. *Lancet Neurol.* 6, 442–455 (2007). [PubMed: 17434099]
11. Thomson AD, Jeyasingham MD, Pratt OE & Shaw GK Nutrition and alcoholic encephalopathies. *Acta Med. Scand* 717 (Suppl.), 55–65 (1987).
12. Todd KG & Butterworth RF Early microglial response in experimental thiamine deficiency: an immunohistochemical analysis. *Glia* 25, 190–198 (1999). [PubMed: 9890633]
13. Lieber CS Relationships between nutrition, alcohol use, and liver disease. *Alcohol Res. Health* 27, 220–231 (2003). [PubMed: 15535450]
14. Thomson AD Mechanisms of vitamin deficiency in chronic alcohol misusers and the development of the Wernicke–Korsakoff syndrome. *Alcohol Alcohol.* 35 (Suppl.), 2–7 (2000).
15. Martin PR, Singleton CK & Hiller-Sturmhofel S The role of thiamine deficiency in alcoholic brain disease. *Alcohol Res. Health* 27, 134–142 (2003). [PubMed: 15303623]
16. Galvin R et al. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. *Eur. J. Neurol* 17, 1408–1418 (2010). [PubMed: 20642790]
17. Harper C The neuropathology of alcohol-specific brain damage, or does alcohol damage the brain? *J. Neuropathol. Exp. Neurol* 57, 101–110 (1998). [PubMed: 9600202]
18. Butters N The Wernicke–Korsakoff syndrome: a review of psychological, neuropathological and etiological factors. *Curr. Alcohol* 8, 205–232 (1981). [PubMed: 6806017]
19. Feinberg I, Fein G, Price LJ, Jernigan TL & Floyd TC in *Aging in the 1980s: Psychological Issues* (ed. Poon LW) 71–77 (American Psychological Association, Washington D. C., 1980).
20. Butters N & Brandt J in *Recent Developments in Alcoholism Vol. 3* (ed. Galanter M) 207–226 (Plenum Publishing, New York, 1985). [PubMed: 3883444]
21. Harper CG, Giles M & Finlay-Jones R Clinical signs in the Wernicke–Korsakoff complex: a retrospective analysis of 131 cases diagnosed at necropsy. *J. Neurol. Neurosurg. Psychiatry* 49, 341–345 (1986). [PubMed: 3701343]
22. Caine D, Halliday GM, Kril JJ & Harper CG Operational criteria for the classification of chronic alcoholics: identification of Wernicke’s encephalopathy. *J. Neurol. Neurosurg. Psychiatry* 62, 51–60 (1997). [PubMed: 9010400]
23. Fama R, Marsh L & Sullivan EV Dissociation of remote and anterograde memory impairment and neural correlates in alcoholic Korsakoff syndrome. *J. Int. Neuropsychol. Soc* 10, 427–441 (2004). [PubMed: 15147600]
24. Fama R, Pfefferbaum A & Sullivan EV Visuo-perceptual priming in alcoholic Korsakoff syndrome. *Alcohol. Clin. Exp. Res* 30, 680–687 (2006). [PubMed: 16573587]
25. Sullivan EV, Deshmukh A, Desmond JE, Lim KO & Pfefferbaum A Cerebellar volume decline in normal aging, alcoholism, and Korsakoff’s syndrome: relation to ataxia. *Neuropsychology* 14, 341–352 (2000). [PubMed: 10928737]
26. Kopelman MD, Thomson AD, Guerrini I & Marshall EJ The Korsakoff syndrome: clinical aspects, psychology and treatment. *Alcohol Alcohol.* 44, 148–154 (2009). [PubMed: 19151162]

27. Oscar-Berman M & Ellis RJ Cognitive deficits related to memory impairments in alcoholism. *Recent Dev. Alcohol* 5, 59–80 (1987). [PubMed: 3550918]
28. Dirksen CL, Howard JA, Cronin-Golomb A & Oscar-Berman M Patterns of prefrontal dysfunction in alcoholics with and without Korsakoff's syndrome, patients with Parkinson's disease, and patients with rupture and repair of the anterior communicating artery. *Neuropsychiatr. Dis. Treat* 2, 327–339 (2006). [PubMed: 19412479]
29. Oscar-Berman M in Review of NIAAA's Neuroscience and Behavioral Research Portfolio, NIAAA Research Monograph No. 34 (eds Noronha, Eckardt M & Warren K) 437–472 (NIH, Bethesda, 2000).
30. Giancola PR & Moss HB Executive cognitive functioning in alcohol use disorders. *Recent Dev. Alcohol* 14, 227–251 (1998).
31. Bates ME, Bowden SC & Barry D Neurocognitive impairment associated with alcohol use disorders: implications for treatment. *Exp. Clin. Psychopharmacol* 10, 193–212 (2002). [PubMed: 12233981]
32. Oscar-Berman M & Marinkovic K Alcohol: effects on neurobehavioral functions and the brain. *Neuropsychol. Rev* 17, 239–257 (2007). [PubMed: 17874302]
33. Sullivan EV, Harris RA & Pfefferbaum A Alcohol's effects on brain and behavior. *Alco. Res. Health* 33, 127–143 (2010).
34. Green A et al. The effect of moderate to heavy alcohol consumption on neuropsychological performance as measured by the repeatable battery for the assessment of neuropsychological status. *Alcohol. Clin. Exp. Res* 34, 443–450 (2010). [PubMed: 20028356]
35. Bowden SC Separating cognitive impairment in neurologically asymptomatic alcoholism from Wernicke–Korsakoff Syndrome: is the neuropsychological distinction justified? *Psychol. Bull* 107, 355–366 (1990). [PubMed: 2190253]
36. Squire L & Butters N (eds) *Neuropsychology of Memory* 2nd edn (Guilford Press, New York, 1992).
37. Pitel AL et al. Episodic and working memory deficits in alcoholic Korsakoff patients: the continuity theory revisited. *Alcohol. Clin. Exp. Res* 32, 1229–1241 (2008). [PubMed: 18482159]
38. Sullivan EV et al. Disruption of frontocerebellar circuitry and function in alcoholism. *Alcohol. Clin. Exp. Res* 27, 301–309 (2003). [PubMed: 12605080]
39. Pitel AL et al. Signs of preclinical Wernicke's encephalopathy and thiamine levels as predictors of neuropsychological deficits in alcoholism without Korsakoff's syndrome. *Neuropsychopharmacology* 36, 580–588 (2011). [PubMed: 20962766]
40. Victor M, Adams RD & Collins GH *The Wernicke–Korsakoff Syndrome* (Davis FA, Philadelphia, 1971).
41. Harper CG & Blumbergs PC Brain weights in alcoholics. *J. Neurol. Neurosurg. Psychiatry* 45, 838–840 (1982). [PubMed: 7131020]
42. Skullerud K Variations in the size of the human brain. Influence of age, sex, body length, body mass index, alcoholism, Alzheimer changes, and cerebral atherosclerosis. *Acta Neurol. Scand* 102, 1–94 (1985).
43. Harper CG & Kril JJ in *Alcohol Induced Brain Damage: NIAAA Research Monograph No. 22* (eds Hunt WA & Nixon SJ) 39–69 (NIH, Rockville, 1993).
44. Harper CG, Kril JJ & Holloway RL Brain shrinkage in chronic alcoholics: a pathological study. *Br. Med. J* 290, 501–504 (1985). [PubMed: 3918649]
45. De la Monte SM Disproportionate atrophy of cerebral white matter in chronic alcoholics. *Arch. Neurol* 45, 990–992 (1988). [PubMed: 3415529]
46. Harper C & Kril JJ Brain atrophy in chronic alcoholic patients: a quantitative pathological study. *J. Neurol. Neurosurg. Psychiatry* 48, 211–217 (1985). [PubMed: 3981189]
47. Kril JJ & Butterworth RF Diencephalic and cerebellar pathology in alcoholic and nonalcoholic patients with end-stage liver disease. *Hepatology* 26, 837–841 (1997). [PubMed: 9328301]
48. Phillips SC, Harper CG & Kril J A quantitative histological study of the cerebellar vermis in alcoholic patients. *Brain* 110, 301–314 (1987). [PubMed: 3567526]

49. Harper CG & Kril JJ Corpus callosal thickness in alcoholics. *Br. J. Addict* 83, 577–580 (1988). [PubMed: 3382816]
50. Tarnowska-Dziduszko E, Bertrand E & Szpak G Morphological changes in the corpus callosum in chronic alcoholism. *Folia Neuropathol.* 33, 25–29 (1995). [PubMed: 8673416]
51. Lee ST, Jung YM, Na DL, Park SH & Kim M Corpus callosum atrophy in Wernicke’s encephalopathy. *J. Neuroimaging* 15, 367–372 (2005). [PubMed: 16254403]
52. Harper C et al. The pathophysiology of ‘brain shrinkage’ in alcoholics structural and molecular changes and clinical implications. *Alcohol. Clin. Exp. Res* 29, 1106–1115 (2005).
53. Harding A, Halliday G, Caine D & Kril J Degeneration of anterior thalamic nuclei differentiates alcoholics with amnesia. *Brain* 123, 141–154 (2000). [PubMed: 10611128]
54. Cullen KM, Halliday GM, Caine D & Kril JJ The nucleus basalis (Ch4) in the alcoholic Wernicke–Korsakoff syndrome: reduced cell number in both amnesic and nonamnesic patients. *J. Neurol. Neurosurg. Psychiatry* 63, 315–320 (1997). [PubMed: 9328247]
55. Baker K, Harding A, Halliday G, Kril J & Harper C Neuronal loss in functional zones of the cerebellum of chronic alcoholics with and without Wernicke’s encephalopathy. *Neuroscience* 91, 429–438 (1999). [PubMed: 10366000]
56. Harper C & Kril J An introduction to alcohol-induced brain damage and its causes. *Alcohol Alcohol.* 2 (Suppl.), 237–243 (1994).
57. Kril JJ, Halliday GM, Svoboda MD & Cartwright H The cerebral cortex is damaged in chronic alcoholics. *Neuroscience* 79, 983–998 (1997). [PubMed: 9219961]
58. Harper C & Corbett D Changes in the basal dendrites of cortical pyramidal cells from alcoholic patients—a quantitative Golgi study. *J. Neurol. Neurosurg. Psychiatry* 53, 856–861 (1990). [PubMed: 2266366]
59. McMullen PA, Saint-Cyr JA & Carlen PL Morphological alterations in the rat CA1 hippocampal pyramidal cell dendrites resulting from chronic ethanol consumption and withdrawal. *J. Comp. Neurol* 225, 111–118 (1984). [PubMed: 6539344]
60. Harding AJ, Halliday GM, Ng JL, Harper CG & Kril JJ Loss of vasopressin-immunoreactive neurons in alcoholics is dose-related and time-dependent. *Neuroscience* 72, 699–708 (1996). [PubMed: 9157316]
61. Harper C, Dixon G, Sheedy D & Garrick T Neuropathological alterations in alcoholic brains. Studies arising from the New South Wales Tissue Resource Centre. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 27, 951–961 (2003). [PubMed: 14499312]
62. Harding AJ, Wong A, Svoboda M, Kril JJ & Halliday GM Chronic alcohol consumption does not cause hippocampal neuron loss in humans. *Hippocampus* 7, 78–87 (1997). [PubMed: 9138671]
63. Baker KG, Halliday GM, Kril JJ & Harper CG Chronic alcoholics without Wernicke–Korsakoff syndrome or cirrhosis do not lose serotonergic neurons in the dorsal raphe nucleus. *Alcohol. Clin. Exp. Res* 20, 61–66 (1996). [PubMed: 8651464]
64. Jernigan TL et al. Reduced cerebral grey matter observed in alcoholics using magnetic resonance imaging. *Alcohol. Clin. Exp. Res* 15, 418–427 (1991). [PubMed: 1877728]
65. Sullivan EV et al. *In vivo* mammillary body volume deficits in amnesic and nonamnesic alcoholics. *Alcohol. Clin. Exp. Res* 23, 1629–1636 (1999). [PubMed: 10549995]
66. Sheedy D, Lara A, Garrick T & Harper C Size of mamillary bodies in health and disease: useful measurements in neuroradiological diagnosis of Wernicke’s encephalopathy. *Alcohol. Clin. Exp. Res* 23, 1624–1628 (1999). [PubMed: 10549994]
67. Shear PK, Sullivan EV, Lane B & Pfefferbaum A Mammillary body and cerebellar shrinkage in chronic alcoholics with and without amnesia. *Alcohol. Clin. Exp. Res* 20, 1489–1495 (1996). [PubMed: 8947329]
68. Jernigan TL, Schafer K, Butters N & Cermak LS Magnetic resonance imaging of alcoholic Korsakoff patients. *Neuropsychopharmacology* 4, 175–186 (1991). [PubMed: 2064717]
69. Lenz V et al. Value of MRI findings in Gayet–Wernicke encephalopathy [French]. *J. Neuroradiol* 29, 153–160 (2002). [PubMed: 12447138]
70. Pfefferbaum A et al. Brain gray and white matter volume loss accelerates with aging in chronic alcoholics: a quantitative MRI study. *Alcohol. Clin. Exp. Res* 16, 1078–1089 (1992). [PubMed: 1471762]

71. Pfefferbaum A, Sullivan EV, Mathalon DH & Lim KO Frontal lobe volume loss observed with magnetic resonance imaging in older chronic alcoholics. *Alcohol. Clin. Exp. Res* 21, 521–529 (1997). [PubMed: 9161613]
72. Cardenas VA, Studholme C, Gazdzinski S, Durazzo TC & Meyerhoff DJ Deformation-based morphometry of brain changes in alcohol dependence and abstinence. *Neuroimage* 34, 879–887 (2007). [PubMed: 17127079]
73. Pfefferbaum A et al. Increase in brain cerebrospinal fluid volume is greater in older than in younger alcoholic patients: a replication study and CT/MRI comparison. *Psychiatry Res* 50, 257–274 (1993). [PubMed: 8177924]
74. Pfefferbaum A, Lim KO, Desmond JE & Sullivan EV Thinning of the corpus callosum in older alcoholic men: a magnetic resonance imaging study. *Alcohol. Clin. Exp. Res* 20, 752–757 (1996). [PubMed: 8800395]
75. Estruch R et al. Atrophy of the corpus callosum in chronic alcoholism. *J. Neurol. Sci* 146, 145–151 (1997). [PubMed: 9077511]
76. Sullivan EV et al. Cerebellar volume deficits and neuropsychological function in alcoholics [abstract]. *Alcohol. Clin. Exp. Res* 22, 63A (1998).
77. Agartz I, Momenan R, Rawlings RR, Kerich MJ & Hommer DW Hippocampal volume in patients with alcohol dependence. *Arch. Gen. Psychiatry* 56, 356–363 (1999). [PubMed: 10197833]
78. Sullivan EV, Marsh L, Mathalon DH, Lim KO & Pfefferbaum A Anterior hippocampal volume deficits in nonamnestic, aging chronic alcoholics. *Alcohol. Clin. Exp. Res* 19, 110–122 (1995). [PubMed: 7771636]
79. Blansjaar B, Vielvoye G, van Dijk J & Rijnders R Similar brain lesions in alcoholics and Korsakoff patients: MRI, psychometric and clinical findings. *Clin. Neurol. Neurosurg* 93, 197–203 (1992).
80. O’Neill J, Cardenas VA & Meyerhoff DJ Effects of abstinence on the brain: quantitative magnetic resonance imaging and magnetic resonance spectroscopic imaging in chronic alcohol abuse. *Alcohol. Clin. Exp. Res* 25, 1673–1682 (2001). [PubMed: 11707642]
81. Pfefferbaum A, Adalsteinsson E & Sullivan EV Dymorphology and microstructural degradation of the corpus callosum: interaction of age and alcoholism. *Neurobiol. Aging* 27, 994–1009 (2006). [PubMed: 15964101]
82. Schroth G, Naegele T, Klose U, Mann K & Petersen D Reversible brain shrinkage in abstinent alcoholics, measured by MRI. *Neuroradiology* 30, 385–389 (1988). [PubMed: 3211313]
83. Carlen PL, Wilkinson DA, Wortzman G & Holgate R Partially reversible cerebral atrophy and functional improvement in recently abstinent alcoholics. *Can. J. Neurol. Sci* 11, 441–446 (1984).
84. Schweinsburg BC et al. Chemical pathology in brain white matter of recently detoxified alcoholics: a 1H magnetic resonance spectroscopy investigation of alcohol-associated frontal lobe injury. *Alcohol. Clin. Exp. Res* 25, 924–934 (2001). [PubMed: 11410730]
85. Fein G, Meyerhoff DJ & Weiner MW Magnetic resonance spectroscopy of the brain in alcohol abuse. *Alcohol Health Res. World* 19, 3056–3314 (1995).
86. Jagannathan NR, Desai NG & Raghunathan P Brain metabolite changes in alcoholism: An *in vivo* proton magnetic resonance spectroscopy (MRS) study. *Magn. Reson. Imaging* 14, 553–557 (1996). [PubMed: 8843367]
87. Seitz D et al. Localized proton magnetic resonance spectroscopy of the cerebellum in detoxifying alcoholics. *Alcohol. Clin. Exp. Res* 23, 158–163 (1999). [PubMed: 10029218]
88. Durazzo TC, Gazdzinski S, Rothlind JC, Banys P & Meyerhoff DJ Brain metabolite concentrations and neurocognition during short-term recovery from alcohol dependence: preliminary evidence of the effects of concurrent chronic cigarette smoking. *Alcohol. Clin. Exp. Res* 30, 539–551 (2006). [PubMed: 16499496]
89. Martin PR et al. Brain proton magnetic resonance spectroscopy studies in recently abstinent alcoholics. *Alcohol. Clin. Exp. Res* 19, 1078–1082 (1995). [PubMed: 7485820]
90. Bartsch AJ et al. Manifestations of early brain recovery associated with abstinence from alcoholism. *Brain* 130, 36–47 (2007). [PubMed: 17178742]
91. Shear PK, Jernigan TL & Butters N Volumetric magnetic resonance imaging quantification of longitudinal brain changes in abstinent alcoholics. *Alcohol. Clin. Exp. Res* 18, 172–176 (1994). [PubMed: 8198216]

92. Pfefferbaum A et al. Longitudinal changes in magnetic resonance imaging brain volumes in abstinent and relapsed alcoholics. *Alcohol. Clin. Exp. Res* 19, 1177–1191 (1995). [PubMed: 8561288]
93. Gazdzinski S, Durazzo TC & Meyerhoff DJ Temporal dynamics and determinants of whole brain tissue volume changes during recovery from alcohol dependence. *Drug Alcohol Depend.* 78, 263–273 (2005). [PubMed: 15893157]
94. Sullivan EV & Marsh L Hippocampal volume deficits in alcoholic Korsakoff's syndrome. *Neurology* 61, 1716–1719 (2003). [PubMed: 14694035]
95. Kim E et al. Mammillothalamic functional connectivity and memory function in Wernicke's encephalopathy. *Brain* 132, 369–376 (2009). [PubMed: 19036763]
96. Schulte T, Sullivan EV, Muller-Oehring EM, Adalsteinsson E & Pfefferbaum A Corpus callosal microstructural integrity influences interhemispheric processing: a diffusion tensor imaging study. *Cereb. Cortex* 15, 1384–1392 (2005). [PubMed: 15635059]
97. Pfefferbaum A, Adalsteinsson E & Sullivan EV Supratentorial profile of white matter microstructural integrity in recovering alcoholic men and women. *Biol. Psychiatry* 59, 364–372 (2006). [PubMed: 16125148]
98. Pfefferbaum A, Adalsteinsson E & Sullivan EV Dymorphology and microstructural degradation of the corpus callosum: interaction of age and alcoholism. *Neurobiol. Aging* 27, 994–1009 (2006). [PubMed: 15964101]
99. Sullivan EV Compromised pontocerebellar and cerebellothalamocortical systems: speculations on their contributions to cognitive and motor impairment in nonamnestic alcoholism. *Alcohol. Clin. Exp. Res* 27, 1409–1419 (2003). [PubMed: 14506401]
100. Leiner HC, Leiner AL & Dow RS Cognitive and language functions of the human cerebellum. *Trends Neurosci* 16, 444–447 (1993). [PubMed: 7507614]
101. Chanraud S et al. Diffusion tensor tractography in mesencephalic bundles: relation to mental flexibility in detoxified alcohol-dependent subjects. *Neuropsychopharmacology* 34, 1223–1232 (2009). [PubMed: 18615012]
102. Zahr NM, Pitel AL, Chanraud S & Sullivan EV Contributions of studies on alcohol use disorders to understanding cerebellar function. *Neuropsychol. Rev* 20, 280–289 (2010). [PubMed: 20809198]
103. Parks MH et al. Longitudinal brain metabolic characterization of chronic alcoholics with proton magnetic resonance spectroscopy. *Alcohol. Clin. Exp. Res* 26, 1368–1380 (2002). [PubMed: 12351932]
104. Schmahmann J & Sherman J The cerebellar cognitive affective syndrome. *Brain* 121, 561–579 (1998). [PubMed: 9577385]
105. Meyerhoff DJ Brain spectroscopic imaging, morphometry, and cognition in social drinkers and recovering alcoholics. *Alcohol. Clin. Exp. Res* 29, 153–154 (2005).
106. Sullivan EV, Rosenbloom MJ, Lim KO & Pfefferbaum A Longitudinal changes in cognition, gait, and balance in abstinent and relapsed alcoholic men: relationships to changes in brain structure. *Neuropsychology* 14, 178–188 (2000). [PubMed: 10791858]
107. Rosenbloom MJ, Pfefferbaum A & Sullivan EV Recovery of short-term memory and psychomotor speed but not postural stability with long-term sobriety in alcoholic women. *Neuropsychology* 18, 589–597 (2004). [PubMed: 15291737]
108. Shatz CJ MHC class I: an unexpected role in neuronal plasticity. *Neuron* 64, 40–45 (2009). [PubMed: 19840547]
109. Luna-Medina R et al. NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. *J. Neurosci* 27, 5766–5776 (2007). [PubMed: 17522320]
110. He J & Crews FT Increased MCP-1 and microglia in various regions of the human alcoholic brain. *Exp. Neurol* 210, 349–358 (2008). [PubMed: 18190912]
111. Barres BA The mystery and magic of glia: a perspective on their roles in health and disease. *Neuron* 60, 430–440 (2008). [PubMed: 18995817]
112. Cook CC, Hallwood PM & Thomson AD B vitamin deficiency and neuropsychiatric syndromes in alcohol misuse. *Alcohol Alcohol.* 33, 317–336 (1998). [PubMed: 9719389]

113. Butterworth RF, Kril JJ & Harper CG Thiamine-dependent enzyme changes in the brains of alcoholics—relationship to the Wernicke–Korsakoff syndrome. *Alcohol. Clin. Exp. Res* 17, 1084–1088 (1993). [PubMed: 8279670]
114. Morgan MY Alcohol and nutrition. *Br. Med. Bull* 38, 21–29 (1982). [PubMed: 7093633]
115. Tallaksen CM, Bøhmer T & Bell H Blood and serum thiamin and thiamin phosphate esters concentrations in patients with alcohol dependence syndrome before and after thiamin treatment. *Alcohol. Clin. Exp. Res* 16, 320–325 (1992). [PubMed: 1317136]
116. Harper C, Rodriguez M, Gold J & Perdices M The Wernicke–Korsakoff syndrome in Sydney—a prospective necropsy study. *Med. J. Aust* 149, 718 (1988).
117. Blass JP & Gibson GE Abnormality of a thiamine-requiring enzyme in patients with Wernicke–Korsakoff syndrome. *N. Engl. J. Med* 297, 1367–1370 (1977). [PubMed: 927453]
118. Mukherjee AB et al. Transketolase abnormality in cultured fibroblasts from familial chronic alcoholic men and their male offspring. *J. Clin. Invest* 79, 1039–1043 (1987). [PubMed: 3558815]
119. Nixon PF, Kaczmarek MJ, Tate J, Kerr RA & Price J An erythrocyte transketolase isoenzyme pattern associated with the Wernicke–Korsakoff syndrome. *Eur. J. Clin. Invest* 14, 278–281 (1984). [PubMed: 6434322]
120. Coy JF et al. Molecular cloning of tissue-specific transcripts of a transketolase-related gene: implications for the evolution of new vertebrate genes. *Genomics* 32, 309–316 (1996). [PubMed: 8838793]
121. Guerrini I et al. Direct genomic PCR sequencing of the high affinity thiamine transporter (SLC19A2) gene identifies three genetic variants in Wernicke Korsakoff syndrome (WKS). *Am. J. Med. Genet. B Neuropsychiatr. Genet* 137B, 17–19 (2005). [PubMed: 16015585]
122. Loh EW et al. Association between variants at the GABA_Aβ2, GABA_Aα6 and GABA_Aγ2 gene cluster and alcohol dependence in a Scottish population. *Mol. Psychiatry* 4, 539–544 (1999). [PubMed: 10578235]
123. Singleton CK & Martin PR Molecular mechanisms of thiamine utilization. *Curr. Mol. Med* 1, 197–207 (2001). [PubMed: 11899071]
124. Liu J et al. Patterns of gene expression in the frontal cortex discriminate alcoholic from nonalcoholic individuals. *Neuropsychopharmacology* 31, 1574–1582 (2006). [PubMed: 16292326]
125. Mayfield RD et al. Patterns of gene expression are altered in the frontal and motor cortices of human alcoholics. *J. Neurochem* 81, 802–813 (2002). [PubMed: 12065639]
126. Iwamoto K et al. Decreased expression of *NEFH* and *PCP4/PEP19* in the prefrontal cortex of alcoholics. *Neurosci. Res* 49, 379–385 (2004). [PubMed: 15236863]
127. Etheridge N, Lewohl JM, Mayfield RD, Harris RA & Dodd PR Synaptic proteome changes in the superior frontal gyrus and occipital cortex of the alcoholic brain. *Proteomics Clin. Appl* 3, 730–742 (2009). [PubMed: 19924264]
128. Sokolov BP, Jiang L, Trivedi NS & Aston C Transcription profiling reveals mitochondrial, ubiquitin and signaling systems abnormalities in postmortem brains from subjects with a history of alcohol abuse or dependence. *J. Neurosci. Res* 72, 756–767 (2003). [PubMed: 12774316]
129. Weimbs T & Stoffel W Proteolipid protein (PLP) of CNS myelin: positions of free, disulfide-bonded, and fatty acid thioester-linked cysteine residues and implications for the membrane topology of PLP. *Biochemistry* 31, 12289–12296 (1992). [PubMed: 1281423]
130. Boison D & Stoffel W Disruption of the compacted myelin sheath of axons of the central nervous system in proteolipid protein-deficient mice. *Proc. Natl Acad. Sci. USA* 91, 11709–11713 (1994). [PubMed: 7526402]
131. Lewohl JM, Dodd PR, Mayfield RD & Harris RA Application of DNA microarrays to study human alcoholism. *J. Biomed. Sci* 8, 28–36 (2001). [PubMed: 11173973]
132. Matsuda-Matsumoto H, Iwazaki T, Kashem MA, Harper C & Matsumoto I Differential protein expression profiles in the hippocampus of human alcoholics. *Neurochem. Int* 51, 370–376 (2007). [PubMed: 17513015]
133. Alexander-Kaufman K, Harper C, Wilce P & Matsumoto I Cerebellar vermis proteome of chronic alcoholic individuals. *Alcohol. Clin. Exp. Res* 31, 1286–1296 (2007). [PubMed: 17561921]

134. Alexander-Kaufman K, Dedova I, Harper C & Matsumoto I Proteome analysis of the dorsolateral prefrontal region from healthy individuals. *Neurochem. Int* 51, 433–439 (2007). [PubMed: 17590479]
135. Alexander-Kaufman K, James G, Sheedy D, Harper C & Matsumoto I Differential protein expression in the prefrontal white matter of human alcoholics: a proteomics study. *Mol. Psychiatry* 11, 56–65 (2006). [PubMed: 16172612]
136. Kashem MA, James G, Harper C, Wilce P & Matsumoto I Differential protein expression in the corpus callosum (splenium) of human alcoholics: a proteomics study. *Neurochem. Int* 50, 450–459 (2007). [PubMed: 17141922]
137. Kashem MA, Harper C & Matsumoto I Differential protein expression in the corpus callosum (genu) of human alcoholics. *Neurochem. Int* 53, 1–11 (2008). [PubMed: 18513832]
138. Lishman WA Cerebral disorder in alcoholism: syndromes of impairment. *Brain* 104, 1–20 (1981). [PubMed: 7470838]
139. Crabbe JC Alcohol and genetics: new models. *Am. J. Med. Genet* 114, 969–974 (2002). [PubMed: 12457395]
140. Chen YC et al. Pharmacokinetic and pharmacodynamic basis for overcoming acetaldehyde-induced adverse reaction in Asian alcoholics, heterozygous for the variant *ALDH2*2* gene allele. *Pharmacogenet. Genomics* 19, 588–599 (2009). [PubMed: 19584771]
141. Enoch MA Genetic and environmental influences on the development of alcoholism: resilience vs. risk. *Ann. NY Acad. Sci* 1094, 193–201 (2006). [PubMed: 17347351]
142. Caspi A et al. Role of genotype in the cycle of violence in maltreated children. *Science* 297, 851–854 (2002). [PubMed: 12161658]
143. Foley DL et al. Childhood adversity, monoamine oxidase a genotype, and risk for conduct disorder. *Arch. Gen. Psychiatry* 61, 738–744 (2004). [PubMed: 15237086]
144. Rangaswamy M et al. A functional MRI study of visual oddball: evidence for frontoparietal dysfunction in subjects at risk for alcoholism. *Neuroimage* 21, 329–339 (2004). [PubMed: 14741671]
145. Wiers RW, Sergeant JA & Gunning WB Psychological mechanisms of enhanced risk of addiction in children of alcoholics: a dual pathway? *Acta Paediatr. Suppl* 404, 9–13 (1994). [PubMed: 7841640]
146. Whipple SC & Noble EP Personality characteristics of alcoholic fathers and their sons. *J. Stud. Alcohol* 52, 331–337 (1991). [PubMed: 1875706]
147. Blum K et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. *J. Psychoactive Drugs* 32 (Suppl. i–iv), 1–112 (2000).
148. Mathalon DH, Pfefferbaum A, Lim KO, Rosenbloom MJ & Sullivan EV Compounded brain volume deficits in schizophrenia–alcoholism comorbidity. *Arch. Gen. Psychiatry* 60, 245–252 (2003). [PubMed: 12622657]
149. Sullivan EV et al. Contribution of alcohol abuse to cerebellar volume deficits in men with schizophrenia. *Arch. Gen. Psychiatry* 57, 894–902 (2000). [PubMed: 10986553]
150. Krystal JH et al. The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. *Neurotox. Res* 10, 235–252 (2006). [PubMed: 17197373]
151. Cargiulo T Understanding the health impact of alcohol dependence. *Am. J. Health Syst. Pharm* 64, S5–S11 (2007).
152. Ceballos NA, Nixon SJ, Phillips JA & Tivis R Semantic processing in alcoholics with and without antisocial symptomatology. *J. Stud. Alcohol* 64, 286–291 (2003). [PubMed: 12713204]
153. Grant BF et al. Co-occurrence of 12-month alcohol and drug use disorders and personality disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. *Arch. Gen. Psychiatry* 61, 361–368 (2004). [PubMed: 15066894]
154. Kessler RC, Chiu WT, Demler O, Merikangas KR & Walters EE Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. *Arch. Gen. Psychiatry* 62, 617–627 (2005). [PubMed: 15939839]
155. New South Wales Tissue Resource Centre. ‘Brain Bank’ [online], <http://sydney.edu.au/medicine/pathology/trc/index.php> (2010).

156. Harper C et al. How important are brain banks for alcohol research? *Alcohol. Clin. Exp. Res* 27, 310–323 (2003). [PubMed: 12605081]
157. Pfefferbaum A, Sullivan EV, Adalsteinsson E, Garrick T & Harper C Postmortem MR imaging of formalin-fixed human brain. *Neuroimage* 21, 1585–1595 (2004). [PubMed: 15050582]
158. Dedova I et al. The importance of brain banks for molecular neuropathological research: the New South Wales Tissue Resource Centre experience. *Int. J. Mol. Sci* 10, 366–384 (2009). [PubMed: 19333451]
159. Garrick T, Azizi L, Merrick J & Harper C Brain donation for research, what do people say? *Intern. Med. J* 33, 475 (2003).
160. Glaw XM et al. Brain donation: who and why? *Cell Tissue Bank* 10, 241–246 (2009). [PubMed: 19184533]
161. Fein G & Landman B Treated and treatment-naive alcoholics come from different populations. *Alcohol* 35, 19–26 (2005). [PubMed: 15922134]
162. Nakamura K et al. Acetaldehyde adducts in the brain of alcoholics. *Arch. Toxicol* 77, 591–593 (2003). [PubMed: 14574447]
163. Bora PS & Lange LG Molecular mechanism of ethanol metabolism by human brain to fatty acid ethyl esters. *Alcohol. Clin. Exp. Res* 17, 28–30 (1993). [PubMed: 8452205]
164. Coyle JT & Puttfarcken P Oxidative stress, glutamate, and neurodegenerative disorders. *Science* 262, 689–695 (1993). [PubMed: 7901908]
165. Tsai GE et al. Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. *Am. J. Psychiatry* 155, 726–732 (1998). [PubMed: 9619143]
166. Ikegami Y et al. Increased TUNEL positive cells in human alcoholic brains. *Neurosci. Lett* 349, 201–205 (2003). [PubMed: 12951203]
167. Brooks PJ Brain atrophy and neuronal loss in alcoholism: a role for DNA damage? *Neurochem. Int* 37, 403–412 (2000). [PubMed: 10871692]
168. Climent E, Pascual M, Renau-Piqueras J & Guerri C Ethanol exposure enhances cell death in the developing cerebral cortex: role of brain-derived neurotrophic factor and its signaling pathways. *J. Neurosci. Res* 68, 213–225 (2002). [PubMed: 11948666]
169. Fadda F & Rossetti ZL Chronic ethanol consumption: from neuroadaptation to neurodegeneration. *Prog. Neurobiol* 56, 385–431 (1998). [PubMed: 9775400]
170. Butterworth RF Hepatic encephalopathy—a serious complication of alcoholic liver disease. *Alcohol Res. Health* 27, 143–145 (2003). [PubMed: 15303624]
171. Felipo V & Butterworth RF Neurobiology of ammonia. *Prog. Neurobiol* 67, 259–279 (2002). [PubMed: 12207972]
172. Zahr NM et al. Glutamate and glutamine changes induced by ethanol treatment in the rat brain detectable at 3T. In *Proc. ISMRM 18th Annual Meeting* 917 (Stockholm, Sweden, 2010).
173. Mousseau DD, Perney P, Layrargues GP & Butterworth RF Selective loss of pallidal dopamine D2 receptor density in hepatic encephalopathy. *Neurosci. Lett* 162, 192–196 (1993). [PubMed: 8121627]
174. Donaldson J, LaBella FS & Gesser D Enhanced autoxidation of dopamine as a possible basis of manganese neurotoxicity. *Neurotoxicology* 2, 53–64 (1981). [PubMed: 15622724]
175. Niemela O et al. Antibodies against acetaldehyde-modified protein epitopes in human alcoholics. *Hepatology* 7, 1210–1214 (1987). [PubMed: 2445642]
176. Albano E Alcohol, oxidative stress and free radical damage. *Proc. Nutr. Soc* 65, 278–290 (2006). [PubMed: 16923312]
177. Yokoyama H et al. Experimental hepatitis induced by ethanol after immunization with acetaldehyde adducts. *Hepatology* 17, 14–19 (1993). [PubMed: 8423034]
178. Horner M, Behrens UJ, Worner T & Lieber CS Humoral immune response to acetaldehyde adducts in alcoholic patients. *Res. Comm. Chem. Pathol. Pharmacol* 54, 3–12 (1996).
179. Qin L et al. Increased systemic and brain cytokine production and neuroinflammation by endotoxin following ethanol treatment. *J. Neuroinflammation* 5, 10 (2008). [PubMed: 18348728]
180. Crews FT & Nixon K Mechanisms of neurodegeneration and regeneration in alcoholism. *Alcohol* 44, 115–127 (2009). [PubMed: 18940959]

181. Phillips SC Cytoprotective value of lysine, penicillamine, and pyridoxal phosphate against the neurotoxicity of acetaldehyde. *Toxicol. Appl. Pharmacol* 98, 553–560 (1989). [PubMed: 2497555]
182. Butterworth RF Pathophysiology of alcoholic brain damage: synergistic effects of ethanol, thiamine deficiency and alcoholic liver disease. *Metab. Brain Dis* 10, 1–8 (1995). [PubMed: 7596324]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Key points

- Alcohol can cause a spectrum of untoward structural and functional changes in the brain
- The spectrum of disruption includes alcohol-related brain damage at one end and complications such as hepatic encephalopathy, Wernicke encephalopathy, Korsakoff syndrome, Marchiafava–Bignami disease and central pontine myelinolysis at the other
- The clinical diagnoses of alcohol-related brain damage and even Wernicke encephalopathy can be difficult to make, and many cases of these conditions are missed
- Changes to the brain associated with alcohol intake are regionally specific and can affect both gray and white matter; some of these changes are reversible with abstinence
- Pathogenic mechanisms associated with alcoholism are under investigation, with neuroinflammation currently receiving particular attention

Box 1 |**Prelude to alcoholism**

Alcoholism is the product of multiple interacting factors including complex genetics, the environment, predisposing personality characteristics, and psychiatric comorbidities.¹³⁹ Variation in genes that modify the metabolism of ethanol, such as those encoding alcohol dehydrogenase¹⁴⁰ or aldehyde dehydrogenase,¹⁴⁰ has been shown to influence the risk of this condition. Environmental factors that increase vulnerability to alcoholism include severe childhood trauma (for example, emotional, physical or sexual abuse), maternal depression, and lack of peer or family support.¹⁴¹ An example of a gene–environment interaction that may contribute to the development of alcoholism is the influence of the environment on monoamine oxidase A (MAO-A), an enzyme that is important for the normal functioning of the serotonergic system. Studies have shown that young boys who experience a traumatic event can develop low levels of MAO-A expression, and that this decrease in MAO-A levels correlates with an increase in antisocial behavior, an antecedent of alcohol addiction.^{142,143}

The offspring of individuals with alcoholism can display mild dysfunction of the frontal cortex,¹⁴⁴ expressed as personality traits such as impulsivity, aggressiveness and perseveration, that increase their risk for alcoholism.^{145,146} Similarly, the mesolimbic dopaminergic system, which subserves reward-dependent behaviors, may be dysfunctional (that is, it confers an attenuated response to natural reward in certain individuals), thereby increasing the risk of severe alcoholism.¹⁴⁷ Common psychiatric illnesses associated with alcoholism include schizophrenia,^{148,149} bipolar disorder,¹⁵⁰ major depression,¹⁵¹ antisocial personality disorder,^{152,153} and general anxiety disorder.¹⁵⁴

Box 2 |**EFNS guidelines for diagnosis, therapy and prevention of WE**

- The clinical diagnosis of WE should take into account the different presentations of clinical signs between individuals with and without alcoholism; although the prevalence of WE is higher in the former than the latter group, WE should be suspected in all clinical conditions that could lead to thiamine deficiency
- The clinical diagnosis of WE in patients with alcoholism requires the presence of two of the following four signs: dietary deficiencies, eye signs, cerebellar dysfunction, and either an altered mental state or mild memory impairment
- Total thiamine levels in a blood sample should be measured immediately before thiamine administration
- MRI should be used to support the diagnosis of acute WE in patients both with and without alcoholism
- Thiamine is indicated for the treatment of suspected or manifest WE, and should be administered before any carbohydrate at a dose of 200 mg three times daily, preferably intravenously
- The overall safety of thiamine is very good
- After bariatric surgery, thiamine status should be monitored for at least 6 months and be accompanied by parenteral thiamine supplementation
- Parenteral thiamine should be given to all at-risk individuals admitted to an emergency room
- Patients who die from symptoms suggesting WE should have an autopsy

Derived from Galvin, R. *et al.* (2010).¹⁶ Abbreviations: EFNS, European Federation of Neurological Societies; WE, Wernicke encephalopathy.

Box 3 |**The New South Wales Tissue Resource Centre**

For the past 25 years, the New South Wales Tissue Resource Centre ‘brain bank’¹⁵⁵ has provided much of the postmortem tissue (fresh-frozen and formalin-fixed) used by research groups throughout the world to explore the effects of alcohol on the brain.^{156–158} The validity of research using brain bank material largely depends on careful clinical and pathological characterization of each case, precise matching to control cases, and appropriate storage. Brain bank tissue has been used for structural and molecular studies and to test hypotheses developed from animal models and *in vivo* studies. To ensure the long-term success of the brain bank, their premortem, ‘in-life’ donor program carefully details the lifestyle and medical histories of individuals who have committed to donating their tissue on their death.^{159,160} An important advantage of this tissue is that it is not restricted to the small sample of patients with alcoholism who are in treatment (estimated to be 25% of the total population of individuals with alcoholism in the USA), a limitation of *in vivo* studies, which typically rely on treatment-seeking patients.¹⁶¹

Box 4 |**Select pathophysiological mechanisms underlying ARBD****Ethanol-specific effects**

- Toxic metabolites of ethanol such as acetaldehyde or fatty acid ethyl esters can accumulate and lead to adduct formation, which can disorder lipids, interrupt mitochondrial function, and induce neuronal damage^{162,163}
- Ethanol increases the generation of reactive oxygen species (such as nitric oxide and lipid peroxidation products), which can accumulate and cause DNA damage, inhibition of gene expression, and neuronal death^{164–167}
- Ethanol lowers brain-derived neurotrophic factor levels and, hence, may impair intracellular signaling pathways involved in cell survival, growth and differentiation, thereby enhancing natural cell death¹⁶⁸
- Removal of ethanol causes brain disinhibition, dysregulation of glutamate release and uptake, and stimulation of NMDA receptors that mediate excitotoxicity¹⁶⁹

Thiamine deficiency

- Thiamine deficiency leads to low levels of thiamine pyrophosphate and, hence, impairment of several biochemical pathways in the brain, including carbohydrate metabolism (for energy production), lipid metabolism (for production and maintenance of myelin), and amino acid metabolism (for production of glucose-derived neurotransmitters; for example, glutamic acid and γ -aminobutyric acid)¹⁰

Liver dysfunction

- A liver directly damaged by the toxic effects of ethanol is unable to remove neurotoxic substances such as ammonia and manganese from blood;¹⁷⁰ accumulation of ammonia affects cerebral blood flow, metabolism and astrocytic function,^{171,172} while manganese at high levels can affect the dopaminergic system, enhance oxidative stress, and induce neurotoxicity^{173,174}

Synergistic effects

- Acetaldehyde protein adduct formation¹⁷⁵ or oxidative stress¹⁷⁶ may induce inflammatory liver damage,¹⁷⁷ potentially resulting in a generalized immune response¹⁷⁸ and, consequently, central inflammation^{110,179,180} and neuronal degeneration¹⁸¹
- Liver dysfunction¹⁸² or thiamine deficiency¹¹³ can contribute to astrocytic pathology, which may compromise glutamate homeostasis and enhance NMDA-receptor-mediated excitotoxicity

Abbreviations: ARBD, alcohol-related brain damage; NMDA, *N*-methyl-D-aspartate.

Review criteria

Articles were selected on the basis of their contribution to the field of alcohol-related brain damage research, with a particular focus on neuropathological and neuroimaging studies in humans. Referenced articles were mostly identified from MEDLINE using access search engines PubMed and NLM Gateway. Articles were retrieved using keywords such as “alcohol”, “ethanol”, “alcoholism”, “brain damage”, “white matter loss”, “atrophy”, “neuropathology”, “Wernicke encephalopathy”, “Korsakoff psychosis”, “Wernicke–Korsakoff syndrome”, “thiamine deficiency”, “pathogenesis”, “neuroimaging”, “genomics” and “proteomics”. All articles cited were published in English and most represent peer-reviewed original research articles. This Review aimed to include the most recent pathological and radiological data; however, many articles date back to the 1970s and 1980s when much of the original neuropathology research was performed. Some review articles were also cited and their reference lists scrutinized. Related citation lists generated by PubMed searches were also a useful source of references.




Figure 1 | Brain regions targeted by alcohol-related disease. Figure courtesy of A. Pfefferbaum, SRI International, CA, USA and E. V. Sullivan, Stanford University, CA, USA.




Figure 2 |. Interactions between alcohol consumption and thiamine deficiency.




Figure 3 | Functions and associated brain regions targeted by alcohol abuse and alcoholism. Figure courtesy of A. Pfefferbaum, SRI International, CA, USA and E. V. Sullivan, Stanford University, CA, USA.




Figure 4 | Graded brain-volume deficits in alcoholism and its sequelae. T1-weighted MRI scans from **a** | a 63-year-old healthy control male, **b** | a 59-year-old man with alcoholism, and **c** | a 63-year-old man with WKS. Graded enlargement of the ventricles (indicating shrinkage of the surrounding tissue) can be observed from the healthy control to the individual with WKS. Sagittal (left column), axial (middle column) and coronal (right column) brain images are shown. Abbreviation: WKS, Wernicke–Korsakoff syndrome. Figure courtesy of A. Pfefferbaum, SRI International, CA, USA.